Hybrid06 June 2022

GCOM Congress

4th Global Conference on Myositis 2022

Share this page

icon
icon
icon

Introduction

Dermatomyositis (DM) is a rare immune-mediated myopathy characterised by chronic inflammation of the skin and muscles, leading to cutaneous rashes and progressive, mainly proximal, muscle weakness. Patients with dermatomyositis have a 10-year survival rate of approximately 50%.

The ProDERM study was the first pivotal randomised clinical trial to evaluate IVIg for dermatomyositis.

In an initial 16-week double-blind placebo-controlled period, patients were randomised to receive either high-dose octagam® 10% (2g/kg) or placebo every four weeks. At Week 16, 78.7% (37/47) of patients receiving octagam® 10% were composite Total Improvement Score (TIS) responders compared with 43.8% (21/48) of patients receiving placebo.

Cutaneous DM Disease Area and Severity Index (CDASI) is a 1-page instrument with common and responsive elements and is feasible to use in daily clinical practice for monitoring DM skin disease. CDASI will be explained in the symposium and study results related to this measure will be also discussed.

In DM around 70% of patients has disease specific autoantibodies. Presence of autoantibodies correlate with distinct clinical manifestations. Cases with autoantibodies will also be presented.

Programme

This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This program was developed for use outside the U.S., is intended for non-U.S. HCPs, and is to be used in accordance with local laws and regulations.

Learn more about the ProDERM trial

Watch Prof. Rohit Aggarwal, Medical Director of the Arthritis and Autoimmunity Center at the University of Pittsburgh School of Medicine and a member of the ProDERM study Steering Committee, providing insights on the study
Share this page
icon
icon
icon